In close partnership with an international client base and often working with just a few grams of precious API material, Onyx Scientific performs highly specific polymorph screening at all stages of the drug discovery process, to both pinpoint as many crystal forms as possible, for IP protection, and to select the candidate with optimal solid-state properties.
“Polymorphs are best discovered sooner rather than later and the ultimate goal is to make sure you have the best one ” explains Tony Flinn, CEO, Onyx Scientific. “Choosing an appropriate form demands systematic screening and characterization. At Onyx we utilise a 96 well plate work flow combined with 2D X-ray Powder Diffraction, high throughput Raman Spectroscopy and an automated Zinsser Crissy platform”.
Recognised as a major strength, Onyx Scientifics’
Typical work programs offered in the Onyx GMP facility, include:
Mini Screens – initial, early stage polymorph screening (where material and/or budget are limited)
Standard Screens – identification of as many solid-forms as possible with in a fixed time period
Macro Screens – a complete polymorphism study with stability testing and scale-up
In addition to solid-state polymorph screening, Onyx Scientifics’
MHRA certified and conforming to international GMP standards, Onyx Scientifics’
# # #
About Onyx Scientific:
Onyx Scientific Ltd, provides solid-form research services to the international pharmaceutical and biotech industries throughout the various stages of a drug-discovery process, including: polymorph screening; salt selection; physicochemical property determinations;